Novo CEO Doustdar On What’s New For Ozempic, Wegovy, GLP-1s, Obesity
Novo president and chief executive officer Mike Doustdar talked about Ozempic, Wegovy, new GLP-1 medications, weight loss and obesity and the company's new rebrand
We haven't written up this one. Forbes has the full story — the link below goes straight to it.